Dimension doses first patient in Phase I/II trial of DTX301 for OTC deficiency

US-based biopharmaceutical firm Dimension Therapeutics has started dosing patients in a Phase I/II clinical trial of DTX301 to treat ornithine transcarbamylase (OTC) deficiency.

Source: Drug Development Technology - August 31, 2017 Category: Pharmaceuticals Source Type: news